"Bind-Encapsulate-Destroy"

NanoViricides

Incorporated

Stock Symbol:
NNVC
(NYSE American)

Broad-spectrum Nanomedicines
NV-CoV-2 and NV-CoV-2-R
Clinical: to Attack the SARS-CoV-2 Virus and its Variants
Pre-Clinical: RSV, MPOX, others…

Presentation at the
BIO International Convention 2023
June 5, 2023

Boston Convention & Exhibition Center (BCEC), Boston, MA

Presented by:

Anil R. Diwan, PhD

President & Exec. Chairman

adiwan@nanoviricides.com

Disclosure Statement

NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC). This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only.

NanoViricides, Inc.(www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Coronaviruses, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the "Company) regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are "forward-looking statements" within the meaning of Section 27A of the Securities18 Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Presentation Layout

- NanoViricides Clinical Asset: NV-CoV-2 Broad-Spectrum Antiviral
- NanoViricides Clinical-Ready Assets:
  - NV-387 (API of NV-CoV-2) for Other Antiviral Applications
  - NV-387-R (NV-387 encapsulating Remdesivir) - Broad- Spectrum, Curative
  - NV-HHV-1 - Skin Cream for Treatment of Shingles
- NanoViricides Platform Technology Assets
  - NanoViricides Technology Platform for Drug Encapsulation
  - NanoViricides Technology Platform for Drug Development
- COVID Overview
- Developing Drugs that Virus May Not Escape due to Mutations
- SARS-CoV-2 Therapeutics Development - Clinical Stage
- Industry-Leading Platform Technology Exclusively Licensed
- Our Own cGMP-Capable Manufacturing, R&D, and Nanomedicine Characterization Integrated Facility Enables Rapid Development and Potential for Early Commercialization Revenues On Our Own

NanoViricides Drug Products : Clinical Asset, NV-CoV-2 for COVID

- NV-CoV-2: Treatment of COVID and certain cases of Long COVID
  - API NV-387, Various NV-CoV-2 Drug Product Formulations
  - Broad-Spectrum, Pan-coronavirus Drug - “Resistance is Futile"
  - Highly Effective and Extremely Safe in Pre-Clinical Models
  - Excellent PK in monkey and rodent animal models
- Orally Bio-available! Two Oral Formulations in Clinical Trials
  - NV-CoV-2 Oral Syrup (OS) - titrate per BW
  - NV-CoV-2 Oral Gummies (OG) - fixed dose form
- Also NV-CoV-2 Solution for Injection, Infusion, and Inhalation (SI)
- Phase Ia/Ib of OS, OG - Safety and Tolerability; Human PK Profile
  - Healthy Volunteers - PK in both SAD (Ph1a) and MAD (Ph1b)
  - Also Collect Clinical Efficacy Parameters
    - COVID Patients - Mild to Moderate, PCR +Ve Disease
    - Ph1b MAD, for Phase II/III Dose Regime Selection

NanoViricides Drug Products : Clinical-Ready Assets

- NV-HHV-1: Skin Cream for treatment of Shingles Rash
  - IND-enabling Studies Completed
- NV-387: Other Anti-Viral Applications -> Phase II
  - Elucidating the Broad-Spectrum Nature of NV-387
  - Working on RSV, Other HSPG-binding Viruses
- NV-CoV-2-R: Encapsulates Remdesivir within NV-387 -> Phase II
  - Extremely Broad-Spectrum Antiviral, like Antibiotics for Bacteria!
  - Substantially Improves Remdesivir PK/PD Profile
  - Enables Synergistic Drug Action
  - Blocks Both (i) Re-infection & (ii) Replication Parts of Virus Life Cycle
- Expect Complete Cure of Many Viruses Against Which Both NV-387 and Remdesivir are Individually Effective *in vitro*

NanoViricides ENABLER Platform Technology Asset: NanoViricides Technology Platform for Drug Encapsulation

- The nanoviricides technology platform is proven to be capable of encapsulating and protecting APIs improving their PK/PD and bioactivity
- Enables Long Acting Acute Timeframe (~ 24 - 72 hours); Tailorable
- Administration Routes: Oral, Transdermal, Topical Ocular, Injectable Ocular, I.V. Injection, I.V. Infusion, Lung Inhalation…
- Antivirals - Broad-Spectrum, Multi-MoA Means Escape Variants Highly Unlikely
- Potential Cures for Non-Latency Viruses by Blocking Complete Virus Lifecycle (NV-387 blocking Re-Infection Cycle; guest blocking Replication Cycle).
- Application: Pandemic Preparedness; Biodefense, Highly Varying Viruses
- Example: NV-CoV-2-R (NV-387-R)



* 376 (R-SBECD) is Gilead Remdesivir Infusion Formulation. Administered twice on first day, then once daily next 7 days (9 slow-push tail-vein injections), matching Gilead protocol.
* 387-R-Med is Remdesivir encapsulated in NV-387, with RDV concentration at twice that of #376. Administered once on days 0,1,3,5,7 (5 slow-push tail-vein injections).
* NV-387-R-Low is half the concentration of, and administered the same way as NV-387-R-Med.
* NV-387-R-Low, only half the RDV amount injected, but the AUC is equivalent to the Gilead formulation, indicating a significant improvement in unmodified RDV in plasma.
* Consistently, doubling of AUC of RDV given as NV-387-R-Med is observed when the total RDV injected was about equal (Med) to that of the Gilead formulation.

NanoViricides ENABLER Platform Technology Asset: NanoViricides Technology Platform for Drug Development

- Specific Site-Directed Ligands for Binding to Viral Surface Glycoproteins
- Expected to Preferentially Attack Virus Particles and Virus-Infected Cells Sparing Uninfected Normal Cells
  - Infected Cells Exhibit Viral Glycoproteins and Viruses on Their Surface
- Minimizes Toxicity and Improves PK/PD of Payload APIs
- Rescue Drug Candidates that Do Not Fit Lipinski Criteria
  - Many antiviral agents are highly hydrophobic, and are dropped during early pre-clinical studies
- Example: NV-HHV-1 (Comprises covalently attached ligand designed for herpesvirus family) can be used as an encapsulant to carry additional guests (for example, replication inhibitors, maturation inhibitors, assembly inhibitors, etc.) against herpesviruses -
- To Build Drugs for - Specificity to Virus or Virus Family, with Escape Variant Generation Highly Unlikely (Multi-MoA), and Potential Cures for non-Latency Viruses

Traditional Drug Development Methodologies Have Not Resulted in an Effective Drug Against SARS-CoV-2 Variants

NanoViricides is Different

Our Novel Approach Has Already ENABLED :

- Variant-Proof Drugs
- Blocking the Complete Viral LifeCycle
  - Without Requiring Help from the Host's Own Defense Systems
  - Important for Severe Cases

Cure is Possible If Both of
(a) Viral Re-Infection Cycle, and
(b) Viral Replication Cycle
Arms of the Viral LifeCycle are Blocked

Normal Virus LifeCycle



NanoViricides Technology Platform Defines A Novel Paradigm in Antiviral Medicines Enables NV-CoV-2, NV-CoV-2, NV-CoV-2-R Nanomachines

- A "NanoViricide" is a Nanomachine Designed to Attack the Virus Particle
  - 1. Bind the Virus Particle (Multiple-Point, "NanoVelcro" Effect)
  - 2. Engulf the Virus Particle ("Shape-shifting" Nanoviricde Micelles)
  - 3. Render the Virus Particle Incapable of Infecting Cell ("Lipid-Lipid Fusion" Driven Dismantling of Virus Surface Glycoproteins Required for Cell Entry and Fusion)
- Using Shape-Shifting TheraCour® Polymeric Micelle-based Technologies



Novel Platform Technology: A nanoviricide® is a Cell Mimic

Artificial Cell Bio-Mimicry

Viral Resistance to the Nanoviricide Drug is Unlikely

because Even as the Virus Mutates,

It Still Binds to the Same Cell Surface Receptor(s), in the Same Fashion



A nanoviricide "Looks Like" a Human Cell to the Virus

A nanoviricide is large enough for a virus particle to latch onto it.
Yet small enough to circulate readily in the body.
A nanoviricide wraps around the virus particle and encapsulates it,
by using the virus particle's very same ability to enter a cell!

Nanoviricides Dismantling MCMV Virus Particle

Control



MCMV Virus Particle
Containing Multiple Capsids

Treated





Virus Dismantled;
Capsids Spilling Out
A: intermediate state;
C: total dismantling

© All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NNVC)

NV-CoV-2-R is Designed to Block the SARS-CoV-2 Virus Lifecycle Completely - A Potential Cure

- DUAL MODE ATTACK - Possibly the Only Drug in Development to do this!
- Its NV-CoV-2 Component Nanomachine Blocks the Virus Re-infection Cycle
  - Block Virus Attack from Virus Particles in Fluids Outside of Cells
- Its Encapsulated Remdesivir Component Blocks the Virus Replication Cycle
  - Blocks Production of New Virus Particles Inside Cells

Normal Virus LifeCycle



Dual Blockade of Virus LifeCycle by NV-CoV-2-R



COVID-19 Pandemic Emergency Declared Over; Variants Widespread and Endemic; Seasonal: "Virus is Not Done Yet"



- Variants Fuel New Waves, Since ca. December 2019
- No End in Sight Regarding New Variants Appearing in the Future
- Major Waves - Alpha, Delta, Omicron - Omicron - Omicron!
- Waves of Infection Cycling Around the Globe
- Entering Omicron XBB.1.16, XBB.1.5, BQ1, BQ1.1 Multi-Variant Wave in the USA
- Vaccines Provided Partial Protection from Hospitalization and Death, but -
  - Variants are Continuously Driving Vaccine's Efficacy Downwards
  - Virus Continues to Make People Sick and Spread Despite Vaccination
- Vaccines Not Providing the Needed Long Term Effect- Only 3-6 Months Immunity
- Boosters with the Same Vaccine Cause "Immune Misdirection Effects"
- Boosters Containing Prior Vaccine Cause "Antigenic Original Sin Effect"
- "Antibody-Dependent Enhancement" (ADE) is the Most Dreaded form
  - In ADE, the Variant uses the (misdirected) Antibodies to hitch a ride and Infect Vaccinated Persons More Strongly than Unvaccinated Ones
  - SARS-CoV-1 Has Been Shown to be Capable of ADE
  - Therefore, the World Cannot Discount the Possibility for SARS-CoV-2 ADE

SARS-CoV-2 Virus is On Course to Become Endemic; Seasonal

Variants Will Continue to Evolve, Resistant to Vaccines and Antibodies
Vaccines Have Not Provided Long Term Immunity
Limitations of Antibody Therapies

No "Curative Immunity"
from Vaccines or from Natural Immunity after Infection

Virus Successfully Infects Pets and Other Animals
Enabling Zoonotic Sources for Future Break-outs

Therefore:
SARS-CoV-2 is Not Being Eliminated from Population

So:
We Need an Effective, Broad-Spectrum, Pan-Coronavirus Drug
to Enable Society to Go Back to Normal Functioning

An Effective Drug is the Weapon Needed for Closing the COVID-19 Threat Once and For All as the World Must Learn to Live with the Endemic SARS-CoV-2 (Variants) of the Future

SADLY: NONE YET!



Current Scenario - SARS-CoV-2 Therapeutics



- Remdesivir is the Only Approved Drug for Severe, Hospitalized Cases
  - Its Effectiveness is Limited by (a) Metabolism and (b) Toxicity
- Antibodies- No Active Antibodies Remain As of Now! All EUAs Revoked!!
- ORAL DRUGS so far EUA Only for Mild to Moderate Disease
  - Molnupiravir (Merck-Ridgeback) Not Very Effective
    - Also Mutagenic and Toxic - ICMR (India) Recommended Against It
    - NIH Has Strongly Restricted Recommendations for Use
  - Paxlovid (Pfizer) Has Limited Applicability, Several Warnings, but is Somewhat More Effective than Molnupiravir
    - Only 0.9 Log_{10} Reduction in Viral Load (>10% Virus Remains)
    - Not Effective in <65 years old Adults With No High Risk Attributes
- Many Other Failures in Clinical Trials

SADLY:
NO EFFECTIVE, BROAD-SPECTRUM, PAN-CORONAVIRUS DRUGS YET!

(EUA = Emergency Use Authorization)

NanoViricides - TWO COVID Drug Candidates in Development

Phase Ia/Ib - NV-CoV-2 :

A nanoviricide® designed to attack the virus and destroy it, thus Blocking Re-Infection

NV-CoV-2-R :

Amplifies the Power of Remdesivir to Block Replication, and Synergistically Adds it to the Power of NV-CoV-2 to Block ReInfection

NV-CoV-2

Has Shown Strong Effectiveness in Animal Models that Used ACE2-Binding Coronavirus Causing Lethal Lung Infection Emulating SARS-CoV-2 Clinical Disease

NV-CoV-2-R

NV-CoV-2-R Has Shown Stronger Effectiveness in Same Animal Models than NV-CoV-2, as Expected

However, It Has a Longer Development Path than NV-CoV-2

Both NV-CoV-2 and NV-CoV-2-R Found to be Substantially Superior to Remdesivir in Lethal SARS-Emulating Coronavirus Infection Animal Studies

Lethal SARS-Emulating Animal Study Demonstrated Strong Efficacy				
Treatment	Survival, Days	Body Weight Loss (Less is Better), Day 5	Lung Histopathology at Day 5	General Organ Toxicity
UnInfected or Vehicle Control	5	deceased at 5 days	Abundant Characteristic Plaques	Yes
Remdesivir (RDV)	7.5	~15%	Moderate Characteristic Plaques	Yes
NV-CoV-2	14	~10%	Almost Normal	No
NV-CoV-2-R (Matched RDV, Half NV-CoV-2 content)	16	~8%	Almost Normal	Some
Infection protocol	Lethal infection with 10e4 particles of hCoV-NL63 instilled directly into lungs of Sprague-Dawley Rats			

Note: hCoV-NL63 is a Coronavirus that uses same receptor (ACE2) as, and causes the same pathology but with reduced severity compared to, SARS-CoV-2 that causes COVID-19.
hCoV-NL63 infection causes a much lower severity than does SARS-CoV-2 in humans.

NV-CoV-2 Demonstrated Broad-Spectrum, Pan-Coronavirus Activity

Broad-Spectrum, Pan-Coronavirus Activity:

NV-CoV-2 Has Shown Strong Effectiveness in Animal Models that Used ACE2-Binding Coronavirus Causing Lethal Lung Infection Emulating SARS-CoV-2 Clinical Disease

Effective Against All Tested, Unrelated, Coronaviruses:

- **hCoV-NL63**
  a milder seasonal coronavirus that uses the same receptor (ACE2) and produces the same lung pathology as SARS-CoV-2
- **hCoV-229E**
  a seasonal coronavirus that uses a different receptor (APN)
- **SARS-CoV-2 Pseudovirus (BSL2)**

Means NV-CoV-2 Will Remain Effective Against SARS-CoV-2 Emerging Variants For a Very Very Long Time

NV-CoV-2 is in Phase Ia/Ib Clinical Trials

Pre-Clinical Safety/Toxicology: Extremely Safe in Animal Studies

Primates, Rats, Mice

Orally Effective Formulations Manufactured

NV-CoV-2 Oral "Gummies"

An Easy to Use, Soft-candy-like Formulation with fixed dose for Children and Adults

NV-CoV-2 Oral Syrup

Easy to Use, Adjustable Dosing for Infants and Children

Injectable Formulations Manufactured

NV-CoV-2 Solution for Injection, Infusion, and Inhalation

Injection for Out-Patient Moderate to Severe Cases

Infusion for Hospitalized Cases

Infusion + Direct Lung Inhalation for the Strongest Effect for Hospitalized Patients with Severe Lung Disease

NV-CoV-2 for Phase Ia/Ib Clinical Trials

NV-CoV-2 cGMP-Compliant Manufacture is Established at NanoViricides cGMP-Capable Manufacturing Facility in Shelton, CT
Process Development, Quality Assurance, etc.
for Drug Substance
and for Drug Products
Completed

Process Scale-Up
Completed Up to ~ 5 Kg Drug Substance per Batch

Clinical Batch Production Completed

Clinical Trial Application is Approved

Clinical Drug Product Shipped to Our Collaborator in End of April, 2023

Clinical Trial Site Readiness Tasks Completed

Start of Recruitment and First Dosing Awaited

Highly Effective, Variant-Proof, Safe NanoViricide Drug Candidates Both NV-CoV-2 and NV-CoV-2-R Have Demonstrated:

Strong Effectiveness Against:

+ SARS-CoV-2 Pseudovirions
  (Uses ACE2)
+ Human Coronavirus NL-63
  (Uses ACE2, but Distinctly Different Virus from SARS-CoV-2)
+ Human Coronavirus 229E
  (Does Not Use ACE2)

Therefore:

Both of These Drugs Should Remain Effective Against All Variants of SARS-CoV-2

Broad-Spectrum, Pan-Coronavirus Drugs

Useful Beyond the COVID-19 Pandemic

Strong Effectiveness in a Lethal Rat Model of SARS-CoV Lung Disease Caused by an ACE2-Binding CoronaVirus Infection

Should Translate to Similarly Strong Effectiveness in Human Clinical Studies

Note that We DID NOT USE Genetically Modified Animals that Suppress Drug Metabolism. Therefore, Our Animal Studies Should Have Better Physiological Correlation with Human Clinical Trials than Other Reported Studies Using Such Animals.

Excellent Safety in Cell Cultures as well as Rodent and Primate Animal Models

Non-GLP & GLP Studies Completed
MTD of NV-CoV-2 ~1,500 mg/Kg

NV-CoV-2 is Extremely Safe:
Non-Immunogenic, Non-Allergenic, Non-genotoxic, Non-mutagenic…

GLP Safety Toxicology Studies of NV-CoV-2 Completed

- No Evidence of Adverse Effects
- GLP neuro-pulmonary safety pharmacology study in rats concluded:
  - The intravenous administration of NV-CoV-2 at doses of 25, 50 and 100 mg/kg did not affect respiratory function in rats
- GLP cardiovascular function study in the NHP cynomolgus monkeys concluded:
  - Intravenous infusion of NV-CoV-2 at 25, 37.5, and 50 mg/kg did not have any toxicologic effects on cardiac rhythm or ECG morphology
  - No significant effects on blood pressure and heart rate

Non-GLP Safety Toxicology Studies of Both NV-CoV-2 and NV-CoV-2-R Completed Strong Safety at Very High Dosage Levels

- Rats dosed at up to 562 mg/kg body weight by tail vein intravenous injection on Days 0,1,3,5,7,9 for a total of 3,375mg/kg dose of NV-CoV-2 showed no side effects
- Rats dosed at up to 309 mg/kg body weight by tail vein intravenous injection on Days 0,1,3,5,7,9 for a total of 1,855mg/kg dose of NV-CoV-2-R showed no side effects
- No evidence of any severe adverse reactions was observed during the administration or during the study period and at postmortem examination
- NV-CoV-2, NV-CoV-2-R and Vehicle groups tolerated the compounds similarly
- The body fluids and fecal analysis showed no significant difference between the groups
- Histopathological examination showed no changes either in the areas of small intestine or large intestine
- No changes in organ weight or histology were observed in all dose groups.

NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability

- Clinical Product Supply Capability for Mostly All of Our Nanoviricides
- Significant Time and Cost Savings
- Potential for Manufacturing Commercial Product - Market Entry & Early Revenues

- Nanomedicines Characterization Facility
- Virology BSL-2 Certified Lab
- Protect Proprietary Technology & Intellectual Property
- Rapid Transfer from Lab Bench to cGMP Manufacture
- Highly Customizable and Flexible Pharma Manufacturing Capability
- Skin Creams, Eye Drops, Gels, Injectables, Oral…

Recap

- “Resistance is Futile” - Antiviral Nanomachines Designed to Destroy Viruses Despite Viral Mutations
- Broad and Deep Pipeline based on Platform Technology
- Next Generation NanoViricides (with Encapsulated Additional Action) Already in Development
- In-house cGMP Manufacture Enabling Early Commercial Revenues On Its Own
- Major Regulatory Progress and Milestones to Occur Throughout Next Several Years
- Strong Asset Position
- Expert team
- Valuation

Strong Executive Team

Anil R. Diwan, PhD
President & Exec. Chairman

Co-Founder
Led Uplisting to NYSE-American Exchange in 2013
Raised $65M
Co-Inventor of Nanoviricides® & of TheraCour ®
25+ years Leadership & Entrepreneurial experience
Key Patents, Several NIH SBIR Awards
PhD (Biochem Eng - Rice), BTech (ChemEng - IITB)

Randall W. Barton, PhD
CSO and Acting CRO

30+ Years of Pharmaceutical Industry Experience in Drug Discovery and Pre-clinical Regulatory Development
Former Director of In-Vitro Cardiovascular Research at Boehringer Ingelheim
Nevirapine (Virammune™) Development
Visiting Faculty at the University of Connecticut Medical School, Farmington, CT

Meeta R. Vyas, MBA
CFO

30+ years Experience in Corporate Performance Improvement, Finance, M&A, EBITDA Growth...
Previously: Principal, The Gores Group; Director, Kamylon Capital; CEO, Signature Brands, Inc. (a public company, known for “Mr. Coffee”); Ran $1B GE Appliances Division; Consultant, McKinsey & Company
MBA (Fin.) Columbia, BS (ChemEng) MIT

Jayant Tatake, PhD
VP, R&D

30+ Years of Pharmaceutical Industry Experience in Drug Discovery, Manufacturing, QA/QC, CRO
Synthesis, Scale-up, Formulations, and Pharmaceutical cGMP Expertise
Former Asst. Director, Pharma. Analytics, InterPharm, Inc.
Co-Inventor of Nanoviricides® & TheraCour®
PhD UICT, Bombay

Board of Directors

Anil R. Diwan, PhD
President & Exec. Chairman

Co-Founder, Led Uplisting to NYSE-Amer. in 2013, Raised $100M+, Co-Inventor of Nanoviricides® & of TheraCour ® 30+ years Leadership & Entrepreneurial experience

Not an Independent Board Member
Director and Chairman Since Founding in 2005

Mak Jawadekar, PhD ✔

35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in Pfizer Global R&D. Business and Research experience in joint ventures, alliance management, contracting, pharma R&D, drug delivery, clinical supply manufacture, etc. Global experience working with United States, Europe, India, Japan, China.

Independent Board Member since February, 2020

Hon'ble Theodore "Todd" Rokita, JD ✔

Presently Attorney General, State of Indiana. Former US Rep. from Indiana (4 terms since 2010). Served on several House Committees. Co-owner, Apex Benefits Group, Inc. Extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.

Independent Board Member since May, 2020

Brian M. Zucker, CPA ✔

30+ years of experience as a CPA specializing in the securities industry. A Partner at CFO Financial Partners, LLC (https://www.cfopartners.com/). Also serves as the CFO and Financial Operations Principal for numerous broker dealers and hedge funds. Partner at RRBB Accountants & Advisors. CFO of EIG Energy Partners Capital Markets, LLC. Ex-Senior Consultant at Deloitte Haskins & Sells and at Price Waterhouse. Mr. Zucker holds several FINRA licenses.

Independent Board Member since November, 2020

✔ = Independent Board Member